Is XLRN or NOBL a better dividend investment in 2026?

XLRN currently yields 1.12% with a 5% 5-year dividend growth rate. NOBL yields 2.14% with 5% growth. The better choice depends on your goal: NOBL offers higher current income.

What is the dividend yield difference between XLRN and NOBL?

XLRN has a forward dividend yield of 1.12% ($2.00/share annually). NOBL yields 2.14% ($2.27/share annually). The yield gap is 1.02 percentage points.

Home › Compare › XLRN vs NOBL

XLRN vs NOBL: Dividend Comparison 2026

XLRN yields 1.12% · NOBL yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NOBL wins by $1.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

XLRN

● Live price

1.12%

Share price

$178.75

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.3K

Annual income

$120.31

Full XLRN calculator →

NOBL

● Live price

2.14%

Share price

$106.01

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.8K

Annual income

$246.19

Full NOBL calculator →

Portfolio growth — XLRN vs NOBL

📍 NOBL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	XLRN	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, XLRN + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

XLRN pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XLRN

Annual income on $10K today (after 15% tax)

$95.10/yr

After 10yr DRIP, annual income (after tax)

$102.26/yr

NOBL

Annual income on $10K today (after 15% tax)

$182.19/yr

After 10yr DRIP, annual income (after tax)

$209.26/yr

At 15% tax rate, NOBL beats the other by $107.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XLRN + NOBL for your $10,000?

XLRN: 50%NOBL: 50%

100% NOBL50/50100% XLRN

Portfolio after 10yr

$22.1K

Annual income

$183.25/yr

Blended yield

0.83%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on XLRN right now

XLRN

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$150.00

-16.1% upside vs current

Range: $139.00 — $160.00

NOBL

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XLRN buys

NOBL buys

No recent congressional trades found for XLRN or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricXLRNNOBL

Forward yield	1.12%	2.14% ✓
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$21.3K	$22.8K ✓
Annual income after 10y	$120.31	$246.19 ✓
Total dividends collected	$1.2K	$2.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: XLRN vs NOBL ($10,000, DRIP)

Year	XLRN Portfolio	XLRN Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$10,812	$111.89	$10,914	$214.34	$102.00 → NOBL
2	$11,682	$113.06	$11,897	$218.63	$215.00 → NOBL
3	$12,614	$114.16	$12,952	$222.72	$338.00 → NOBL
4	$13,612	$115.21	$14,086	$226.62	$474.00 → NOBL
5	$14,681	$116.19	$15,302	$230.33	$621.00 → NOBL
6	$15,826	$117.12	$16,607	$233.85	$781.00 → NOBL
7	$17,051	$117.99	$18,007	$237.18	$956.00 → NOBL
8	$18,364	$118.81	$19,508	$240.35	$1.1K → NOBL
9	$19,769	$119.58	$21,116	$243.35	$1.3K → NOBL
10	$21,273	$120.31	$22,841	$246.19	$1.6K → NOBL

XLRN vs NOBL: Complete Analysis 2026

XLRN — Stock

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Full XLRN Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this XLRN vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XLRN vs SCHD XLRN vs JEPI XLRN vs O XLRN vs KO XLRN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.